Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Introduction to Connective Tissues01:11

Introduction to Connective Tissues

Connective tissues are one of the four main tissue types in humans that are extensively present in the body. They are characterized by cells embedded in an extracellular matrix (ECM) composed of a ground substance and three main types of protein fibers— collagen, elastic, and reticular fibers. The ground substance of connective tissues can range from a watery and jelly-like consistency to mineralized and hard. The wide variety of cells in the connective tissues include fibroblasts, osteocytes,...
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
Connective Tissue Cell Types01:22

Connective Tissue Cell Types

Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Other Pulmonary Disorders01:17

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Loose Connective Tissue01:26

Loose Connective Tissue

Loose connective tissue is found between many organs. Its main function is to absorb shock and bind tissues together. It also allows water, salts, and various nutrients to diffuse into cells that are embedded in it or present in adjacent tissues.
Adipose Tissue
Adipose tissue consists primarily of fat storage cells called adipocytes and little extracellular matrix. A large number of capillaries present within adipose tissue allow rapid mobilization of lipid molecules. White adipose tissue is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combining Pirfenidone With Mycophenolate Mofetil for Systemic Sclerosis-Related Interstitial Lung Disease (Scleroderma Lung Study III): An Investigator-Initiated, Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.

ACR open rheumatology·2025
Same author

Incidence rates of interstitial lung disease events among patients with rheumatoid arthritis treated with abatacept or placebo, with background methotrexate: a post hoc pooled analysis from a compendium of clinical trials.

Seminars in arthritis and rheumatism·2025
Same author

Abatacept for the treatment of myositis-associated interstitial lung disease.

Rheumatology (Oxford, England)·2025
Same author

Real-world antifibrotic treatment patterns in patients with idiopathic pulmonary fibrosis: retrospective analyses of two large healthcare administrative databases in the United States.

Therapeutic advances in respiratory disease·2024
Same author

Efficacy and Safety of Admilparant, an LPA<sub>1</sub> Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.

American journal of respiratory and critical care medicine·2024
Same author

Circulating biomarker analyses in a longitudinal cohort of patients with IPF.

American journal of physiology. Lung cellular and molecular physiology·2024

Related Experiment Video

Updated: May 19, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Interstitial lung disease in connective tissue disorders.

Aryeh Fischer1, Roland du Bois

  • 1Division of Rheumatology and Interstitial Lung Disease Program, National Jewish Health, Denver, CO, USA.

Lancet (London, England)
|August 21, 2012
PubMed
Summary

Defining, diagnosing, and treating interstitial lung disease (ILD) linked to connective tissue disease (CTD-ILD) presents challenges. This review examines CTD-ILD prognosis and predictive indices, drawing lessons from other ILD trials for future research.

Related Experiment Videos

Last Updated: May 19, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Pulmonology
  • Rheumatology
  • Medical Research

Background:

  • Interstitial lung disease (ILD) poses significant challenges, particularly when associated with connective tissue diseases (CTD-ILD).
  • CTD-ILD can lead to substantial morbidity and mortality, necessitating improved understanding and management strategies.
  • Current approaches to defining, diagnosing, and treating CTD-ILD require further refinement.

Purpose of the Study:

  • To review prognostic factors and predictive indices for connective tissue disease-associated interstitial lung disease (CTD-ILD).
  • To explore lessons learned from clinical trials in systemic sclerosis-associated ILD and idiopathic pulmonary fibrosis.
  • To apply these insights to enhance future research and clinical studies in CTD-ILD.

Main Methods:

  • Focused review of existing literature and clinical trial data.
  • Analysis of prognostic indicators and outcome prediction in CTD-ILD.
  • Comparative analysis of findings from systemic sclerosis-associated ILD and idiopathic pulmonary fibrosis studies.

Main Results:

  • Prognostic indices for CTD-ILD are being developed, but require further validation.
  • Lessons from systemic sclerosis-associated ILD and idiopathic pulmonary fibrosis trials offer valuable insights into trial design and outcome measures.
  • Identifying reliable predictors of outcome is crucial for effective CTD-ILD management.

Conclusions:

  • Improved definition, diagnosis, and treatment strategies are essential for managing CTD-ILD.
  • Future research should leverage insights from other ILD cohorts to optimize clinical trial design and patient outcomes.
  • Further investigation into prognostic markers will aid in personalized treatment approaches for CTD-ILD.